LILRC1 Inhibitors
LILRC1 inhibitors are chemical compounds designed to modulate the activity of the leukocyte immunoglobulin-like receptor C1 (LILRC1), a receptor found on various immune cells, including macrophages, dendritic cells, and certain lymphocytes. LILRC1 is a member of the larger leukocyte immunoglobulin-like receptor (LILR) family, known for its role in regulating immune responses, particularly through interactions with major histocompatibility complex (MHC) molecules. The inhibition of LILRC1 affects its binding to ligands, which can influence the downstream signaling pathways that mediate immune cell activation, migration, and other cellular processes. Structurally, these inhibitors can vary widely, but they typically feature motifs that allow them to bind to specific sites on the extracellular domain of LILRC1, thereby preventing ligand-receptor interactions.
At a molecular level, LILRC1 inhibitors are often designed to interact with key amino acids within the LILRC1 receptor, either competitively or allosterically. This type of binding disrupts the receptor's conformation or its ability to engage with its natural ligands, which could lead to changes in signal transduction cascades associated with immune modulation. The chemical nature of these inhibitors can range from small organic molecules to larger peptide-based compounds, depending on the desired specificity and binding affinity. In some cases, they may also be optimized for stability, solubility, and other biophysical properties to improve their interaction with the receptor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits phosphatidylinositol 3-kinase (PI3K), disrupting the MAPK cascade and negatively regulating Lilra5. By blocking PI3K activity, Wortmannin indirectly hinders Lilra5-mediated positive regulation of MAPK signaling, impacting cellular processes associated with the MAPK pathway. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Targets Janus kinases (JAKs) and inhibits cytokine signaling. By disrupting JAK-dependent pathways, Ruxolitinib indirectly influences Lilra5's regulatory role in cytokine production. This inhibitor impacts cellular processes associated with cytokine signaling, negatively affecting Lilra5-mediated cytokine regulation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
An inhibitor of Src family kinases, PP2 modulates protein tyrosine kinase activity. By specifically targeting Src family kinases, PP2 disrupts Lilra5-mediated positive regulation of protein tyrosine kinase activity. This inhibition impacts downstream signaling events related to protein tyrosine kinase pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, a key component of the MAPK pathway. SB203580 disrupts Lilra5-mediated positive regulation of the MAPK cascade by specifically targeting p38 MAPK. This inhibition influences downstream events and cellular processes associated with p38 MAPK signaling. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Inhibits JAK2, disrupting cytokine signaling pathways. AG-490's inhibition of JAK2 impacts Lilra5-mediated regulation of cytokine production, influencing cellular processes associated with JAK2-dependent cytokine signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, LY294002 disrupts Lilra5-mediated positive regulation of the MAPK cascade by blocking PI3K activity. This inhibition influences downstream signaling events and cellular processes associated with the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits c-Jun N-terminal kinase (JNK), a component of the MAPK pathway. SP600125 disrupts Lilra5-mediated positive regulation of the MAPK cascade by specifically targeting JNK. This inhibition influences downstream events and cellular processes associated with JNK-dependent signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A multi-targeted kinase inhibitor that inhibits Src family kinases. Dasatinib modulates Lilra5-mediated protein tyrosine kinase activity by targeting Src family kinases, impacting downstream signaling events and cellular processes associated with protein tyrosine kinase pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibits IκBα phosphorylation and NF-κB activation. BAY 11-7082 disrupts Lilra5-mediated cytokine production regulation by blocking NF-κB signaling. This inhibition influences cellular processes associated with the NF-κB pathway, negatively impacting Lilra5-dependent cytokine regulation. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
Inhibits p38 MAPK, a key component of the MAPK pathway. SB202190 disrupts Lilra5-mediated positive regulation of the MAPK cascade by specifically targeting p38 MAPK. This inhibition influences downstream events and cellular processes associated with p38 MAPK signaling. | ||||||